AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
PR Newswire•29/07/2026•03:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.